DSM Capital Partners LLC Acquires 60,432 Shares of Abbott Laboratories $ABT

DSM Capital Partners LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 7.8% during the 3rd quarter, Holdings Channel reports. The firm owned 832,780 shares of the healthcare product maker’s stock after purchasing an additional 60,432 shares during the quarter. Abbott Laboratories comprises approximately 1.6% of DSM Capital Partners LLC’s portfolio, making the stock its 20th biggest holding. DSM Capital Partners LLC’s holdings in Abbott Laboratories were worth $111,543,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. IMG Wealth Management Inc. raised its position in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares in the last quarter. Anfield Capital Management LLC increased its stake in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. Delos Wealth Advisors LLC purchased a new stake in Abbott Laboratories during the second quarter valued at about $32,000. Curio Wealth LLC lifted its stake in Abbott Laboratories by 15,250.0% during the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock worth $42,000 after purchasing an additional 305 shares during the last quarter. Finally, Pineridge Advisors LLC boosted its holdings in shares of Abbott Laboratories by 34.6% in the 2nd quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker’s stock worth $43,000 after purchasing an additional 81 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ABT shares. Sanford C. Bernstein boosted their target price on Abbott Laboratories from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Benchmark started coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They issued a “buy” rating and a $145.00 price objective for the company. BTIG Research reiterated a “buy” rating and issued a $145.00 target price on shares of Abbott Laboratories in a research report on Thursday, November 20th. Finally, Evercore ISI upped their price target on shares of Abbott Laboratories from $142.00 to $144.00 and gave the company an “outperform” rating in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $147.47.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays reaffirmed a constructive view on ABT with a buy/overweight stance and raised its price target, signaling strong analyst confidence that supports further upside. Barclays Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Barclays also increased its price target from $162 to $169 (overweight), implying meaningful upside from current levels and likely supporting buying interest. Benzinga coverage of Barclays PT raise
• Positive Sentiment: Evercore ISI nudged its target up to $144 and maintained an outperform rating, adding another independent analyst vote of confidence for valuation and growth expectations. Evercore ISI adjusts PT on Abbott Laboratories
• Positive Sentiment: Abbott unveiled Libre Assist, an AI-driven feature in the Libre app aimed at in-the-moment meal guidance for people with diabetes — a product extension that could boost user engagement and CGM stickiness. Product innovation at CES supports the narrative of recurring revenue and device ecosystem strength. Abbott’s new Libre Assist app feature
• Neutral Sentiment: Abbott scheduled its Q4 2025 earnings release and conference call for Jan. 22 (pre-market). This is a key near-term catalyst: results and FY guidance will likely drive the next leg of the stock’s move. Abbott hosts conference call for fourth-quarter earnings
• Neutral Sentiment: Studio coverage and comparisons (Zacks) highlight valuation comparisons with peers like Prestige Consumer Healthcare — useful for value-oriented investors, but not a direct stock driver. PBH vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Recent intraday/short-term coverage noting ABT’s outperformance versus the market signals momentum but is not a fundamental change. Abbott (ABT) Rises Higher Than Market: Key Facts

Abbott Laboratories Trading Up 1.2%

Shares of ABT opened at $127.91 on Wednesday. The firm has a fifty day simple moving average of $126.00 and a two-hundred day simple moving average of $129.51. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The stock has a market capitalization of $222.42 billion, a P/E ratio of 16.03, a PEG ratio of 2.09 and a beta of 0.72. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, meeting the consensus estimate of $1.30. The firm had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a $0.63 dividend. The ex-dividend date is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.